Amedisys Q2 2023 Earnings Report

Amedisys EPS Results

• Actual EPS: $1.37
• Consensus EPS: $1.09
• Beat/Miss: Beat by +$0.28
• One Year Ago EPS: $1.47

Amedisys Revenue Results

• Actual Revenue: $552.97 million
• Expected Revenue: $568.18 million
• Beat/Miss: Missed by -$15.21 million
• YoY Revenue Growth: -0.90%

Amedisys Announcement Details

• Quarter: Q2 2023
• Date: 7/26/2023
• Time: Q2 2023 Earnings Release

Amedisys (NASDAQ:AMED), together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.